科伦药业: 关于控股子公司科伦博泰根据一般性授权配售股份的公告

Group 1 - The company announced a share placement agreement involving its subsidiary, Sichuan Kelun Biotech Co., Ltd., to issue 5,918,000 H shares at a price of HKD 331.8 per share [1][2] - The net proceeds from the placement are expected to be HKD 1.943 billion, which will be used for product research and development, clinical trials, registration, manufacturing, commercialization, and enhancing internal R&D capabilities [1][2] - The completion of the placement is subject to certain conditions outlined in the placement agreement, indicating uncertainty regarding the timing and completion of the transaction [1] Group 2 - If the placement is successfully completed, the total shares of Kelun Biotech will change, with the company remaining the controlling shareholder with approximately 53.41% of the shares [2] - The placement aims to meet the funding needs for the continuous development and business growth of Kelun Biotech, thereby broadening its financing channels and positively impacting its operations and long-term development [2]